早期临床试验中的配对和AB/BA交叉设计:更仔细地研究受试者内部变异偏差
Martin J Wolfsegger1, Peixin Xu2, Amy Cotterill3
1Statistical and Quantitative Sciences, Baxalta Innovations GmbH, a Takeda Company, Vienna, Austria.
Pharmaceutical statistics
|March 17, 2026
概括
建议在早期临床试验中采用多个序列交叉设计. 标准配对或AB/BA设计可能会提供对受试者内部变化的偏差估计,影响以后研究的样本大小计算.
科学领域:
- 临床试验方法论 临床试验方法论
- 生物统计学 生物统计学
- 制药指标 (Pharmacometrics) 是一个指标.
背景情况:
- 传统的配对和AB/BA交叉设计在早期临床试验中很常见.
- 这些设计可能会在估计主体内差异时引入偏差.
- 在早期阶段的试验中,对于随机效应估计存在缺乏数学探索.
研究的目的:
- 调查对象内部差异估计对配对和AB/BA交叉设计的偏差.
- 倡导在早期临床研究中使用多个序列交叉设计.
- 突出准确的差异估计对于后续研究规划的重要性.
主要方法:
- 使用正常分布变量对联和AB/BA交叉设计的数据分析.
- 对随机效应的估计进行数学研究.
- 剩余平均平方误差的比较作为对象内部变量的估计.
主要成果:
- 剩余平均平方误差是仅在特定条件下对主体内变量的公正估计器:没有主体对待互动和相同的差异.
- 这些条件在实践中很少得到满足,导致潜在的偏见.
- 配对或AB/BA设计在晚期研究中对样本大小计算的解释潜力有限.
结论:
- 多个序列交叉设计在减轻混杂效应和提供更可靠的差异估计方面具有优势.
- 由于潜在的偏差,在晚期研究中不建议依赖配对或AB/BA设计进行样本大小计算.
- 实施多个序列设计对于强大的早期临床试验规划和准确的样本大小确定至关重要.
相关概念视频
Crossover Experiments
4.7K
Crossover experiments, also called the repeated-measurements design, is a study design in which all experimental units are exposed to all treatments in different periods. Crossover experiments are generally used in psychology, the pharmaceutical industry, agriculture, and medicine.
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
4.7K
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs
367
Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
367
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs
355
Bioequivalence experimental study designs are crucial methodologies used in evaluating and comparing the bioavailability of different drug products. These designs are categorized into various types: completely randomized, randomized block, repeated measures, cross and carry-over, and Latin square designs.Completely randomized designs involve randomly allocating treatments to all subjects participating in the experiment. This allocation is achieved by assigning unique random numbers to subjects...
355
Bioavailability Study Design: Healthy Subjects Versus Patients
201
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
201
Bioavailability Study Design: Single Versus Multiple Dose Studies
316
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
316
Bioequivalence studies: Biowaivers
374
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
374


